<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606537</url>
  </required_header>
  <id_info>
    <org_study_id>KBP5074-1-008</org_study_id>
    <nct_id>NCT04606537</nct_id>
  </id_info>
  <brief_title>Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects</brief_title>
  <official_title>Phase 1, Open-label, Parallel, 2-arm, Fixed-sequence Study to Investigate the Effect of Coadministration of CYP3A4 Inhibitor and CYP3A4 Inducer on the Pharmacokinetics, Safety, and Tolerability of KBP-5074 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KBP Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KBP Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, parallel, 2-arm, fixed-sequence study to investigate the effect of&#xD;
      coadministration of a CYP3A4 inhibitor (Cohort 1, itraconazole multiple dose) and CYP3A4&#xD;
      inducer (Cohort 2, rifampin multiple dose) on the plasma PK of a single dose of KBP-5074 in&#xD;
      healthy male and female subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2020</start_date>
  <completion_date type="Actual">November 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Maximum observed concentration (Cmax)</measure>
    <time_frame>Days 1 and 19 at predose (Cohort 1) and Days 1 and 21 at predose (Cohort 2) and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 240 hours postdose.</time_frame>
    <description>Maximum observed concentration (Cmax) - Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Area under the concentration-time curve from time 0 to infinity (AUC0-∞)</measure>
    <time_frame>Days 1 and 19 at predose (Cohort 1) and Days 1 and 21 at predose (Cohort 2) and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 240 hours postdose.</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity (AUC0-∞) - Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast)</measure>
    <time_frame>Days 1 and 19 at predose (Cohort 1) and Days 1 and 21 at predose (Cohort 2) and at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, and 240 hours postdose.</time_frame>
    <description>Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <condition>Drug Drug Interaction</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Effects of CYP3A4 induction on KBP-5074)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.</description>
    <arm_group_label>Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.</description>
    <arm_group_label>Cohort 2 (Effects of CYP3A4 induction on KBP-5074)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBP-5074</intervention_name>
    <description>0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21</description>
    <arm_group_label>Cohort 1 (Effects of CYP3A4 inhibition on KBP-5074)</arm_group_label>
    <arm_group_label>Cohort 2 (Effects of CYP3A4 induction on KBP-5074)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, of any race, between 18 and 60 years of age, inclusive, at&#xD;
             screening.&#xD;
&#xD;
          -  Body mass index between 18.0 and 32.0 kg/m2, inclusive, at screening.&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory&#xD;
             evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any medical history, as determined by&#xD;
             the investigator not appropriate to participate in this study.&#xD;
&#xD;
          -  Use of any drugs or substances known to be strong or moderate inhibitors or inducers&#xD;
             of CYP3A4 within 30 days prior to study drug administration. Medications will be&#xD;
             reviewed by the medical monitor to determine acceptability for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCabe</last_name>
    <role>Study Director</role>
    <affiliation>KBP Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS Missouri</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KBP5074</keyword>
  <keyword>Healthy Subjects</keyword>
  <keyword>itraconazole</keyword>
  <keyword>rifampin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

